Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms

被引:29
作者
Tamakoshi, K
Kikkawa, F
Maeda, O
Suganuma, N
Yamagata, S
Yamagata, T
Tomoda, Y
机构
[1] NAGOYA UNIV,SCH MED,DEPT OBSTET & GYNECOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN
[2] TOKYO INST TECHNOL,DEPT BIOMOL ENGN,YOKOHAMA,KANAGAWA 227,JAPAN
[3] AICHI CANC CTR,DEPT GYNECOL,NAGOYA,AICHI 464,JAPAN
关键词
hyaluronidase activity; gynaecological cancer; metastasis;
D O I
10.1038/bjc.1997.308
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated hyaluronidase activity in gynaecological normal and malignant tissues. Hyaluronidase activity in culture medium of tissue specimens was detected by hyaluronic acid zymography and quantified by densitometry. Hyaluronidase activity was shown as one dominant band (molecular weight 65 kDa) at pH 3.5. Hyaluronidase activity was significantly higher in normal ovary (P < 0.05) and normal endometrium (P < 0.05) than in normal cervix. One dominant 65-kDa hyaluronidase was expressed in 100% (74 out of 14) of ovarian cancer tissues and in 91% (10 out of 11) of endometrial cancer tissues. However, hyaluronidase activity was not observed in cervical cancer tissues. Hyaluronidase activity was significantly higher in ovarian (P < 0.001) and endometrial (P < 0.07) cancer tissues than in cervical cancer tissue and was significantly higher in ovarian cancer tissue than in endometrial cancer tissue (P < 0.05). These facts suggest that the cancer cells make use of the original characteristic of the organ to invade and metastasize. Moreover, these results reflect the difference in metastatic forms and are suggestive of a strong relationship between hyaluronidase activity and invasion and metastasis of ovarian and endometrial cancers compared with cervical cancer.
引用
收藏
页码:1807 / 1811
页数:5
相关论文
共 24 条
[1]  
ASPLUND T, 1993, CANCER RES, V53, P388
[2]   PROGNOSTIC FACTORS FOR NONCURATIVE GASTRIC-CANCER - UNIVARIATE AND MULTIVARIATE ANALYSES [J].
BABA, H ;
OKUYAMA, T ;
HIROYUKI, O ;
ANAI, H ;
KORENAGA, D ;
MAEHARA, Y ;
AKAZAWA, K ;
SUGIMACHI, K .
JOURNAL OF SURGICAL ONCOLOGY, 1992, 51 (02) :104-108
[3]  
BAKER MS, 1990, CANCER RES, V50, P4676
[4]   SERUM METALLOPROTEINASES AND THEIR INHIBITORS - MARKERS FOR MALIGNANT POTENTIAL [J].
BAKER, T ;
TICKLE, S ;
WASAN, H ;
DOCHERTY, A ;
ISENBERG, D ;
WAXMAN, J .
BRITISH JOURNAL OF CANCER, 1994, 70 (03) :506-512
[5]   THE ROLE OF PROTEOLYTIC-ENZYMES IN CANCER INVASION AND METASTASIS [J].
DUFFY, MJ .
CLINICAL & EXPERIMENTAL METASTASIS, 1992, 10 (03) :145-155
[6]  
DUFFY MJ, 1995, BRIT J CANCER, V71, P105
[7]   GENESIS OF ASCITES IN OVARIAN CANCER [J].
HIRABAYASHI, K ;
GRAHAM, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1970, 106 (04) :492-+
[8]   ANTI-METASTASIS DRUG READY FOR HUMAN TRIALS [J].
JENKS, S .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (04) :220-220
[9]  
KHOKHA R, 1989, INVAS METAST, V9, P391
[10]   ANTIMETASTATIC THERAPY BY URINARY TRYPSIN-INHIBITOR IN COMBINATION WITH AN ANTICANCER AGENT [J].
KOBAYASHI, H ;
SHINOHARA, H ;
GOTOH, J ;
FUJIE, M ;
FUJISHIRO, S ;
TERAO, T .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1131-1137